Advertisement
Screener

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) Graph

NTHI Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $0.00; Research and development $2.65M; Selling, general and administrative (m); Operating expenses $14.07M.
  • 2026-03-31: Revenue (m); Research and development $1.29M; Selling, general and administrative (m); Operating expenses $7.06M.
  • 2025-12-31: Revenue $0.00*; Research and development $1.25M*; Selling, general and administrative (m); Operating expenses $13.70M*.
  • 2025-09-30: Revenue (m); Research and development $715.04K; Selling, general and administrative (m); Operating expenses $6.93M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

NTHI revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$0.00Operating expenses$14.07MOperating income-$14.07MOther income, net-$189.63KResearch & development$2.65MNet income-$14.24M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$0.00$2.65M(m)$14.07M-$14.24M
2026-03-31(m)$1.29M(m)$7.06M-$8.82M
2025-12-31$0.00*$1.25M*(m)$13.70M*-$15.52M*
2025-09-30(m)$715.04K(m)$6.93M-$8.62M
2025-06-30(m)$677.33K(m)$5.71M-$5.68M
2025-03-31$39.99K$998.22K$134.91K$31.94M-$32.33M
2024-09-30(m)$956.73K(m)$2.20M-$2.18M
2024-06-30$20.00K$394.48K(m)$1.30M-$4.52M
2024-03-31$43.00K$614.52K$137.30K$1.59M-$2.94M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30$0.00$3.94M$21.13M-$23.06M
2025-06-30$39.99K$1.64M$37.61M-$38.01M
2024-06-30$63.00K$1.01M$2.89M-$7.46M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30$39.99K$2.39M$44.58M-$46.62M
2024-09-30$63.00K$1.97M$5.09M-$9.65M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-12-31$39.99K$3.64M$58.28M-$62.15M
2024-12-31$83.00K$3.05M$7.23M-$11.90M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92
Telomir Pharmaceuticals, Inc. (TELO)United States$0.084B
Rallybio Corp (RLYB)United States$0.089B
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Lifevantage Corp (LFVN)United States$0.078B15.40
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Valion Bio, Inc. (VBIO)United States$0.077B
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30